These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2172 related articles for article (PubMed ID: 32150489)

  • 1. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
    Gadgeel S; Rodríguez-Abreu D; Speranza G; Esteban E; Felip E; Dómine M; Hui R; Hochmair MJ; Clingan P; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Garon EB; Novello S; Rubio-Viqueira B; Boyer M; Kurata T; Gray JE; Yang J; Bas T; Pietanza MC; Garassino MC
    J Clin Oncol; 2020 May; 38(14):1505-1517. PubMed ID: 32150489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189.
    Rodríguez-Abreu D; Powell SF; Hochmair MJ; Gadgeel S; Esteban E; Felip E; Speranza G; De Angelis F; Dómine M; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Kurata T; Yang J; Pietanza MC; Souza F; Garassino MC
    Ann Oncol; 2021 Jul; 32(7):881-895. PubMed ID: 33894335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study.
    Horinouchi H; Nogami N; Saka H; Nishio M; Tokito T; Takahashi T; Kasahara K; Hattori Y; Ichihara E; Adachi N; Noguchi K; Souza F; Kurata T
    Cancer Sci; 2021 Aug; 112(8):3255-3265. PubMed ID: 34036692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer.
    Borghaei H; Langer CJ; Gadgeel S; Papadimitrakopoulou VA; Patnaik A; Powell SF; Gentzler RD; Martins RG; Stevenson JP; Jalal SI; Panwalkar A; Yang JC; Gubens M; Sequist LV; Awad MM; Fiore J; Saraf S; Keller SM; Gandhi L
    J Thorac Oncol; 2019 Jan; 14(1):124-129. PubMed ID: 30138764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
    Gandhi L; Rodríguez-Abreu D; Gadgeel S; Esteban E; Felip E; De Angelis F; Domine M; Clingan P; Hochmair MJ; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Hui R; Garon EB; Boyer M; Rubio-Viqueira B; Novello S; Kurata T; Gray JE; Vida J; Wei Z; Yang J; Raftopoulos H; Pietanza MC; Garassino MC;
    N Engl J Med; 2018 May; 378(22):2078-2092. PubMed ID: 29658856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
    Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
    Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
    Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.
    Garassino MC; Gadgeel S; Speranza G; Felip E; Esteban E; Dómine M; Hochmair MJ; Powell SF; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Hui R; Garon EB; Kurata T; Gray JE; Schwarzenberger P; Jensen E; Pietanza MC; Rodríguez-Abreu D
    J Clin Oncol; 2023 Apr; 41(11):1992-1998. PubMed ID: 36809080
    [No Abstract]   [Full Text] [Related]  

  • 9. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
    Rudin CM; Awad MM; Navarro A; Gottfried M; Peters S; Csőszi T; Cheema PK; Rodriguez-Abreu D; Wollner M; Yang JC; Mazieres J; Orlandi FJ; Luft A; Gümüş M; Kato T; Kalemkerian GP; Luo Y; Ebiana V; Pietanza MC; Kim HR;
    J Clin Oncol; 2020 Jul; 38(21):2369-2379. PubMed ID: 32468956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study.
    Wu YL; Zhang L; Fan Y; Zhou J; Zhang L; Zhou Q; Li W; Hu C; Chen G; Zhang X; Zhou C; Dang T; Sadowski S; Kush DA; Zhou Y; Li B; Mok T
    Int J Cancer; 2021 May; 148(9):2313-2320. PubMed ID: 33231285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC.
    Awad MM; Gadgeel SM; Borghaei H; Patnaik A; Yang JC; Powell SF; Gentzler RD; Martins RG; Stevenson JP; Altan M; Jalal SI; Panwalkar A; Gubens M; Sequist LV; Saraf S; Zhao B; Piperdi B; Langer CJ
    J Thorac Oncol; 2021 Jan; 16(1):162-168. PubMed ID: 33069888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
    Paz-Ares L; Luft A; Vicente D; Tafreshi A; Gümüş M; Mazières J; Hermes B; Çay Şenler F; Csőszi T; Fülöp A; Rodríguez-Cid J; Wilson J; Sugawara S; Kato T; Lee KH; Cheng Y; Novello S; Halmos B; Li X; Lubiniecki GM; Piperdi B; Kowalski DM;
    N Engl J Med; 2018 Nov; 379(21):2040-2051. PubMed ID: 30280635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up.
    Gadgeel SM; Rodríguez-Abreu D; Halmos B; Garassino MC; Kurata T; Cheng Y; Jensen E; Shamoun M; Rajagopalan K; Paz-Ares L
    J Thorac Oncol; 2024 Aug; 19(8):1228-1241. PubMed ID: 38642841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pemetrexed maintenance with or without pembrolizumab in non-squamous non-small cell lung cancer: A cross-trial comparison of KEYNOTE-189 versus PARAMOUNT, PRONOUNCE, and JVBL.
    Garon EB; Kim JS; Govindan R
    Lung Cancer; 2021 Jan; 151():25-29. PubMed ID: 33285468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
    Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Vandormael K; Riccio A; Yang J; Pietanza MC; Brahmer JR
    J Clin Oncol; 2019 Mar; 37(7):537-546. PubMed ID: 30620668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407.
    Paz-Ares L; Vicente D; Tafreshi A; Robinson A; Soto Parra H; Mazières J; Hermes B; Cicin I; Medgyasszay B; Rodríguez-Cid J; Okamoto I; Lee S; Ramlau R; Vladimirov V; Cheng Y; Deng X; Zhang Y; Bas T; Piperdi B; Halmos B
    J Thorac Oncol; 2020 Oct; 15(10):1657-1669. PubMed ID: 32599071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189.
    Garon EB; Aerts J; Kim JS; Muehlenbein CE; Peterson P; Rizzo MT; Gadgeel SM
    Lung Cancer; 2021 May; 155():53-60. PubMed ID: 33730652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
    Langer CJ; Gadgeel SM; Borghaei H; Papadimitrakopoulou VA; Patnaik A; Powell SF; Gentzler RD; Martins RG; Stevenson JP; Jalal SI; Panwalkar A; Yang JC; Gubens M; Sequist LV; Awad MM; Fiore J; Ge Y; Raftopoulos H; Gandhi L;
    Lancet Oncol; 2016 Nov; 17(11):1497-1508. PubMed ID: 27745820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407.
    Powell SF; Rodríguez-Abreu D; Langer CJ; Tafreshi A; Paz-Ares L; Kopp HG; Rodríguez-Cid J; Kowalski DM; Cheng Y; Kurata T; Awad MM; Lin J; Zhao B; Pietanza MC; Piperdi B; Garassino MC
    J Thorac Oncol; 2021 Nov; 16(11):1883-1892. PubMed ID: 34265431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
    Satouchi M; Nosaki K; Takahashi T; Nakagawa K; Aoe K; Kurata T; Sekine A; Horiike A; Fukuhara T; Sugawara S; Umemura S; Saka H; Okamoto I; Yamamoto N; Sakai H; Kishi K; Katakami N; Horinouchi H; Hida T; Okamoto H; Atagi S; Ohira T; Han SR; Noguchi K; Ebiana V; Hotta K
    Cancer Sci; 2020 Dec; 111(12):4480-4489. PubMed ID: 32926507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 109.